The molecular mechanism underlying hyperpigmentation as an adverse side effect of the anticancer drug, hydroxyurea (HU), was investigated in B16 melanoma cells. HU increased the melanin content and intracellular Ca²⁺ concentration in a dose-dependent manner. These effects were significantly reduced by treatment with the intracellular Ca²⁺ release blockers, dantrolene and 2-aminoethoxidiphenylborate (2-APB). Additionally, HU induced the production of nitric oxide (NO) in a time- and dose-dependent manner, and this was significantly blocked by inhibitors of the increase in intracellular Ca²⁺ levels(bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid/acetoxymethyl ester, dantrolene, and 2- APB). Furthermore, the HU-induced increases in NO and melanin production were significantly suppressed by NG-nitro- L-arginine methyl ester and 2-(4-carboxy-2-phenyl)-4,4,5,5-tetramethylinidazoline-1-oxyl-3-oxide, an NO synthase inhibitor and an NO scavenger, respectively. These results suggest that HU-induced melanogenesis through NO and an increase in intracellular Ca²⁺ levels may be involved in the mechanism of its hyperpigmentation effect.
서 론(Introduction)
방 법(Methods)
결과 및 고찰(Results and Discussion)
결 론(Conclusion)
감사의 말씀(Acknowledgment)
Conflict of Interest
References